From:  Bile-based liquid biopsy in cholangiocarcinoma: current evidence, clinical applications and future directions

 Key studies of bile-based liquid biopsy in CCA and BTC.

Author (year)DesignnTumour typeBiomarker/MethodKey findingBile vs. plasmaMain limitation
Arechederra et al. (2022) [9]Prospective68CCA, PDAC (biliary strictures)cfDNA/NGS (Pan-Cancer panel; Bilemut assay)Overall sensitivity 96.4%, specificity 69.2%; 100% sensitivity in initially benign/indeterminate stricturesBile cfDNA outperformed initial pathological diagnosis; plasma not directly comparedPilot study; mixed biliopancreatic stricture cohort; CCA not analysed as an independent validation subgroup; no external validation cohort
Liu et al. (2025) [11]Prospective10Resectable CCAcfDNA/NGSMutations in 70% bile cfDNA vs. 10% plasma; higher maxAF and TMB in bileBile showed higher mutation detection than plasma for local molecular characterisation in this cohortVery small cohort (n = 10); single centre; limited to resectable disease
Gou et al. (2021) [12]Retrospective42BTC (mixed)cfDNA/NGS (520-gene panel)Mutations in 71.4% bile vs. 53.6% plasma; higher maxAF and tissue concordance in bileBile cfDNA showed higher mutation detection and stronger tissue concordance than plasma in this cohortMixed BTC population; retrospective; limited matched plasma data
Li et al. (2022) [13]Retrospective13BTC (mixed)cfDNA/NGS (425 genes)Bile cfDNA 1,918 ng/mL vs. 63.1 ng/mL plasma; more alterations per sample in bileBile supernatant and pellet detected additional alterations not identified in matched tissue in this cohortSmall cohort; mixed BTC; no prospective validation
He et al. (2023) [10]Retrospective + validationNot stated for CCA alonePancreatobiliary cancercfDNA mutations + methylation/BileScreen assayHigh diagnostic performance; outperformed CA19-9 in specificityBile not directly compared to plasma in same cohortNot CCA-specific; pancreatobiliary mixed population; methylation markers not independently validated in CCA
Shen et al. (2019) [33]Retrospective10BTC (mixed)cfDNA/targeted deep sequencing (150 genes)SNV/Indel sensitivity 94.7%; CNV sensitivity 75%; Lower CNV sensitivity reported in AJCC stage II and distal bile duct tumours, though cohort size limits interpretationFirst study to demonstrate bile cfDNA-based somatic variant detection in BTC using a 150-gene panelVery small cohort; mixed BTC; n = 1 distal CCA
Vedeld et al. (2022) [19]Retrospective273CCA, PSC-associated CCA, PSCDNA methylation/ddPCR (CDO1, CNRIP1, SEPT9, VIM)100% sensitivity, 90% specificity for PSC-associated CCA when diagnosed within 12 months of bile collectionBile not compared to plasma in same cohortRetrospective; PSC-focused; markers not validated for sporadic CCA; no prospective surveillance pathway

BTC: biliary tract cancer; CCA: cholangiocarcinoma; cfDNA: cell-free DNA; ctDNA: circulating tumour DNA; maxAF: maximum allele fraction; NGS: next-generation sequencing; PDAC: pancreatic ductal adenocarcinoma; PSC: primary sclerosing cholangitis; TMB: tumour mutational burden; ddPCR: droplet digital polymerase chain reaction; SNV: single nucleotide variant.